Chinese Journal of Tissue Engineering Research ›› 2015, Vol. 19 ›› Issue (27): 4379-4383.doi: 10.3969/j.issn.2095-4344.2015.27.021

Previous Articles     Next Articles

The influence of taurine on superoxide dismutase and malondialdehyde in liver tissue of rat models of liver fibrosis

Bai Jian1, 2, Xiao Li1, Han Yong1, Bi Li-li1, Kong Xiang-rui2, Wang Xue-liang2, Zhang Li-ping2, Liu Xi-cheng3   

  1. 1Institute of Organ Transplantation, the 309th Hospital of Chinese People’s Liberation Army, Beijng 100091, China; 
    2Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China; 
    3Department of Anesthesiology, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China
  • Online:2015-06-30 Published:2015-06-30
  • Contact: Liu Xi-cheng, Master, Department of Anesthesiology, Shenzhen People’s Hospital, Shenzhen 518020, Guangdong Province, China
  • About author:Bai Jian, M.D., Institute of Organ Transplantation, the 309th Hospital of Chinese People’s Liberation Army, Beijng 100091, China
  • Supported by:

    the Natural Science Foundation of Liaoning Province of China, No. 201101142; a grant from Key Plan Program of Society Development of Liaoning Province of China, No. 2012225018

Abstract:

BACKGROUND: Studies have reported that taurine has a certain therapeutic effect on the disease of various systems, such as nervous system, cardiovascular system, immune system and digestive system. The liver is the main place, also the important target organ, of taurine metabolism. Therefore, the relationship between taurine and hepatopathy has become a hot topic in recent years.
OBJECTIVE: To investigate the influence of taurine on superoxide dismutase and malondialdehyde expression in the liver tissue of rat models of liver fibrosis induced by carbon tetrachloride.
METHODS: Thirty male C57B/L rats of SPF grade were randomly and evenly divided into blank control, model and taurine groups. Rats in the blank control group were intraperitoneally injected with 100% peanut oil of 1 mL/kg, twice a week, in total 10 weeks. Rats in the model group were intraperitoneally injected with peanut oil of 1 mL/kg containing 20% carbon tetrachloride, twice a week, in total 10 weeks. Rats in the taurine group were intraperitoneally injected with peanut oil of 1mL/kg containing 20% carbon tetrachloride, twice a week, in total 10 weeks, and were intragastrically administered taurine of 500 mg/kg per day starting from the 3rd week till the 10th week.
RESULTS AND CONCLUSION: Compared with the blank control group, the serum levels of hyaluronic acid, laminin, type Ⅲ procollagen, type Ⅳ collagen, alanine aminotransferase, aspartate aminotransferase were significantly increased (P < 0.05), the level of superoxide dismutase in the liver tissue was lowered (P < 0.05), the level of malondialdehyde in liver tissue was significantly increased (P < 0.05), and liver index was increased (P < 0.05) in the model group. Pathological examination showed that there were necrosis of liver cells, fat vacuoles, fibrous tissue hyperplasia and inflammatory cell infiltration in the rats of the model group. Compared with the model group, the serum levels of hyaluronic acid, laminin, type Ⅲ procollagen, type Ⅳ collagen, alanine aminotransferase, aspartate aminotransferase were significantly lowered (P < 0.05), the level of superoxide dismutase in the liver tissue was significantly increased (P < 0.05), the level of malondialdehyde in the liver tissue was significantly lowered (P < 0.05), and liver index was significantly decreased (P < 0.05) in the taurine group. Pathological examination showed that there were no inflammatory cell infiltration, fat vacuoles, and fibrous tissue deposition in the liver tissue. The results indicate that taurine can decrease the contents of superoxide dismutase and malondialdehyde, and relieve the degree of liver fibrosis induced by carbon tetrachloride via exerting its antioxidative effects.

中国组织工程研究杂志出版内容重点:肾移植肝移植移植;心脏移植;组织移植;皮肤移植;皮瓣移植;血管移植;器官移植组织工程

Key words: Taurine, Cytoprotection, Liver Fibrosis

CLC Number: